Sarah A. Frech

Corporate Officer/Principal at IOMAI CORPORATION

Consumer Services

Health Technology

Profile

Dr. Sarah A.
Frech is Vice President-Clinical Development at Intercell USA, Inc. and Vice President-Clinical Research at Vtesse, Inc. She received her undergraduate degree from Dartmouth College, a graduate degree from the Johns Hopkins Bloomberg School of Public Health, and a doctorate degree from Washington State University.

Sarah A. Frech active positions

Companies	Position	Start
IOMAI CORPORATION	Corporate Officer/Principal	-

All active positions of Sarah A. Frech

Former positions of Sarah A. Frech

Companies	Position	End
Vtesse, Inc. Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.	Corporate Officer/Principal	-

See the detail of Sarah A. Frech's experience

Training of Sarah A. Frech

Dartmouth College	Undergraduate Degree
Washington State University	Doctorate Degree
Johns Hopkins Bloomberg School of Public Health	Graduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Sarah A. Frech's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Intercell USA, Inc. Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD.	Health Technology
Vtesse, Inc. Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.	Health Technology